Reply to: “Improving the Reporting of Long-Term Effects in the IMpower010 Trial” and “Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity”
Year: 2025
Type: article
Language: en
Topic: Reliability and Agreement in Measurement
Authors and affiliations:
raw_author_name: Enriqueta Felip
raw_affiliation_strings: Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
Enriqueta Felip, MD, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, Chenqi Fu, PhD and Yu Deng, PhD, Genentech Inc, South San Francisco, CA, Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
raw_author_name: Heather A. Wakelee
raw_affiliation_strings: Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
Enriqueta Felip, MD, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, Chenqi Fu, PhD and Yu Deng, PhD, Genentech Inc, South San Francisco, CA, Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
raw_author_name: Chenqi Fu
raw_affiliation_strings: Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
Enriqueta Felip, MD, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, Chenqi Fu, PhD and Yu Deng, PhD, Genentech Inc, South San Francisco, CA, Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
raw_author_name: Yu Deng
raw_affiliation_strings: Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
Enriqueta Felip, MD, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, Chenqi Fu, PhD and Yu Deng, PhD, Genentech Inc, South San Francisco, CA, Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
raw_author_name: Fanny Masson
raw_affiliation_strings: Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
Enriqueta Felip, MD, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, Chenqi Fu, PhD and Yu Deng, PhD, Genentech Inc, South San Francisco, CA, Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
raw_author_name: Barbara Gitlitz
raw_affiliation_strings: Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA
Enriqueta Felip, MD, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, Chenqi Fu, PhD and Yu Deng, PhD, Genentech Inc, South San Francisco, CA, Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA